SCHEMBL3018728

SCHEMBL3018728

COc1ccc(OC)c(S(=O)(=O)C2CCN(c3nc(Cc4ccccc4C)cs3)CC2)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
MAPT P10636 3/20 0.43
RECQL P46063 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
HPGD P15428 2/20 0.40
HSD17B10 Q99714 1/20 0.40
GAA P10253 1/20 0.39
KMT2A Q03164 3/20 0.38
HTR6 P50406 1/20 0.37
THRB P10828 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999613 0.93 MAPT (0.44) ALDH1A1MAPTRECQLL3MBTL1USP2
SCHEMBL3013532 0.93 MAPT (0.39) ALDH1A1MAPTRECQLL3MBTL1USP2
SCHEMBL3011978 0.93 ALDH1A1 (0.44) ALDH1A1MAPTRECQLL3MBTL1USP2
SCHEMBL3007050 0.92 MAPK1 (0.39) ALDH1A1MAPTHTTHPGDGAA
SCHEMBL3017679 0.91 DRD2 (0.39) ALDH1A1MAPTLMNAHTTGAA
SCHEMBL3016935 0.91 L3MBTL1 (0.41) ALDH1A1MAPTRECQLL3MBTL1USP2
SCHEMBL3020441 0.91 ALDH1A1 (0.46) ALDH1A1MAPTRECQLL3MBTL1USP2
SCHEMBL3014447 0.90 ALDH1A1 (0.43) ALDH1A1MAPTRECQLL3MBTL1USP2
SCHEMBL3010895 0.90 MAPT (0.42) ALDH1A1MAPTRECQLL3MBTL1USP2
SCHEMBL3007686 0.89 KMT2A (0.45) ALDH1A1MAPTL3MBTL1USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885MAPT 18/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.